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INTRODUCTION:  Müllerian  adenosarcoma  of the  cervix  with  sarcomatous  overgrowth  and  lymphovas-
cular  invasion  is a  rare and  aggressive  disease.  We  report  a case of  a  young  patient  with  Müllerian
adenosarcoma  with  sarcomatous  overgrowth  in  the  uterine  cervix  and  pelvic  lymph  node  involvement.
The  patient  received  radical  surgery  but not  adjuvant  treatment,  and  the  disease  was  aggressive  with
rapid  relapse.
PRESENTATION  OF  CASE:  A 39-year-old  woman  was  diagnosed  with  Müllerian  adenosarcoma  of  the  cervix
with sarcomatous  overgrowth,  International  Federation  of Gynecology  and Obstetrics  (FIGO)  stage  IB2.
She  underwent  abdominal  radical  hysterectomy  and resection  of the  left external  iliac lymph  nodes  for
suspected  metastatic  involvement  detected  during  surgical  exploration  but  undetected  via imaging.  She
refused  adjuvant  treatment,  and  the  disease  recurred  8  months  after  primary  oncologic  surgery,  with
rapid  local,  regional,  and  bone  relapse.
DISCUSSION:  Our  report  suggests  that  sarcomatous  overgrowth,  a high  mitotic  index, a rhabdomyoblastic
component,  and  lymphovascular  compromise  are  risk  factors  for aggressive  recurrence.  Positron  emission
tomography-computed  tomography  (PET-CT)  was used  to  identify  relapse  locations  in  addition  to  those
detected  via  clinical  examination  of the vaginal  vault.  However,  whether  PET-CT  is indicated  for  the initial
detection  of lymph  node  and  bone  metastases  in  FIGO  stage  IB  tumors  with  surgical  indication  is unclear.
CONCLUSION:  A  young  woman  with  Müllerian  adenosarcoma  of the  cervix  with  sarcomatous  overgrowth
presenting  the  risk  factors  for its recurrence  experienced  a rapid  relapse  after  receiving radical  surgery  but
not adjuvant  therapy.  Control  of this  aggressive  disease  via  sequential  radiotherapy  and  chemotherapy
are  recommended.
© 2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Müllerian adenosarcoma with sarcomatous overgrowth typi-
ally occurs in the uterine corpus, to a lesser extent in the ovaries,
nd rarely in the cervix. The average age at presentation is 60 years
n uterine corpus cases and 41 years in cervical cases. Müllerian
denosarcomas are mixed tumors: they consist of an epithelial
landular component and a mesenchymal component, with the
atter presenting at various stages of dedifferentiation and con-
aining homologous or heterologous tissue. Herein we  describe an
nteresting and unusual case of a Müllerian adenosarcoma with
arcomatous overgrowth in the cervix and pelvic lymph node
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; HR-
PV, high-risk human papilloma virus; MRI, magnetic resonance imaging; PET-CT,
ositron emission tomography-computed tomography.
∗ Corresponding author at: Calle 19N # 7-03, Popayán, Colombia.
E-mail address: davidcorganescorpio@hotmail.com (D.A. Morales F.).
ttp://dx.doi.org/10.1016/j.ijscr.2016.08.044
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
involvement that was not detected via imaging. Abdominal radi-
cal hysterectomy was  performed along with resection of the pelvic
lymph nodes that were suspected for metastatic involvement dur-
ing surgical exploration. The patient refused adjuvant treatment,
and the disease aggressively recurred.
2. Presentation of case
A 39-year-old woman presented with a history of pelvic pain
and bleeding over a 6-month period and a rapidly growing mass
protruding through the uterine cervix. Based on the histopathol-
ogy of a previous tumor biopsy, the ﬁnal diagnosis was Müllerian
adenosarcoma of the cervix with a heterologous component.
Thoracic computed tomography did not identify any lesions.
Magnetic resonance imaging (MRI) of the abdomen and pelvis
revealed a polypoid lesion with heterogeneous T2 signal inten-
sity with hyperintense signal predominance originating in the
left side of the cervix. The lesion measured 59 × 64 × 60 mm
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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rig. 1. (A) Magnetic resonance imaging (MRI) shows a normal endometrium and m
arametrial compromise. (C) A radical hysterectomy specimen. (D) Cervical tumor 
width × depth × length) and extended into and occupied the vagi-
al cavity (Fig. 1A and B). Retroperitoneal lymph nodes were not
dentiﬁed.
The patient was subsequently taken to surgery with a clinical
reoperative diagnosis of Müllerian adenosarcoma of the cervix,
nternational Federation of Gynecology and Obstetrics (FIGO) stage
B2. Abdominal radical hysterectomy was performed along with
esection of the left external iliac lymph nodes that were suspectedrium with a mass originating in the cervix. (B) MRI  shows a cervical tumor without
 with a clear origin in the cervix.
for metastatic involvement during surgical exploration of the pelvic
and para-aortic regions (Fig. 1C and D).
Histopathology revealed an exophytic, friable mass. Macroscop-
ically, it appeared to originate in the cervical wall and protrude
through the external cervical ostium, compromising the anterior
and posterior aspects and the endocervical canal, with the uterine
cavity free of lesions. Microscopically, the lesion was a Mülle-
rian adenosarcoma of the cervix with stromal overgrowth greater
than 25% and a heterologous component (cartilage and rhabdomy-
CASE  REPORT  –  OPEN  ACCESS
D.A. Morales F. et al. / International Journal of Surgery Case Reports 27 (2016) 155–161 157
Fig. 2. (A) Cervical stroma highly inﬁltrated by the sarcoma. The exocervical (arrow) and endocervical (head of arrow) epithelia are histologically normal (20× magniﬁcation,
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lematoxylin & eosin). (B) Close-up of the areas of mesenchymal overgrowth (arrow
nd  benign glands (asterisk) (20× magniﬁcation, hematoxylin & eosin). (C) The pro
asal  layer of the exocervix (arrow) (20× magniﬁcation, Ki67 immunostaining). (D)
blasts); the maximal tumor size was 7.5 cm in diameter (Fig. 2A
nd B).
The tumor exhibited CD10 focal positivity, S100 positivity in
he cartilaginous component, myogenin positivity in the rhab-
omyoblastic component, and cytokeratin cocktail and estrogen
eceptor positivity in the superﬁcial epithelial and glandular com-
onents. The proliferation index as determined via Ki67 staining
as 60% (Fig. 2C). Lymphovascular invasion was  present; 1 left
liac lymph node displayed tumoral compromise (Fig. 2D), whereas
arametrium and proliferative endometrium did not.
Adjuvant ifosfamide chemotherapy and pelvic radiotherapy
lus high-dose intracavitary brachytherapy were recommended,
ut the patient refused owing to personal beliefs and having
een asymptomatic after a successful postoperative course. She
eturned to our hospital 8 months after surgery with light bleed-
ng and pelvic pain radiating to the lower right limb, for which
e performed a complete physical exam and positron emission
omography-computed tomography (PET-CT) and MRI  of the tho-
acic and lumbosacral spine. We  observed local and regional tumor
egrowth in the form of an exophytic mass 6 cm in diameter
riginating in the vaginal vault (Fig. 3A). There was  also a con-
lomeration of right pelvic lymph nodes, each 7 cm in diameter.
hese lesions were visualized clearly via PET-CT, as was  a metastatic
esion in the right pubic ramus (Fig. 3B, C and D).ociated with the areas of cartilage in the heterologous component (head of arrow)
tion index as determined via Ki67 staining was  60%, with normal reactivity in the
h node metastasis at 4× (arrow) and 20× (arrowhead) magniﬁcation.
To treat the patient’s pelvic recurrence and pelvic bone metas-
tasis, external pelvic radiation (conformational technique) was
delivered to the surgical site and margins in fractions of 2 Gy/day up
to 50 Gy/day (planning target volume 1), with posterior reinforce-
ment over the nodal conglomeration and vaginal vault until the
total dose reached 60 Gy. High-dose-rate intracavitary brachyther-
apy of 2.1 Gy was  also administered. After receiving 2.3 Gy of
external pelvic radiation, the patient was  once again asymptomatic,
with a signiﬁcantly improved clinical status and a 95% reduction in
vaginal tumor volume (Fig. 4A). Owing to the excellent pelvic clin-
ical response and the high functional status of the patient (Eastern
Cooperative Oncology Group 0), palliative chemotherapy consist-
ing of ifosfamide and cisplatin was  administered to manage the
metastases.
MRI  revealed osteolytic lesions with diffuse inﬁltration of the
T11, T12, L1, and L2 vertebral bodies with a compression fracture
of T12, left spinal inﬁltration, and medullary canal compromise
(Fig. 4B and C). Hence, the patient received pelvic radiotherapy
and conventional external radiotherapy at a total daily dose of
30 Gy in the thoracolumbar spine. The objectives of palliation were
achieved, and there were no new signs of disease progression. A
total of 21 months elapsed between surgery and the writing of this
report.
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Table 1
Sequentially 1995–2016 cases of Müllerian adenosarcoma of the cervix with sarcomatous overgrowth and other risk factors.
Reference Age PAP/HR-HPV Surgery TS Heterologous MI  SO M × 10 HPF LVI/NODAL ADJUV Follow-Up
Jones and Lefkowitz [14] 33 No TAH 40 mm N N Yes 28 NA/NA No WD 163 m
Park  et al. [11] 37 No TAH + BSO + PL 20 mm N N Yes 20 N/N No WD 9 m
Manoharan et al. [15] 28 No RH 60 mm Striated muscle N Yes >10 P/NA Ifosfamide,
doxorubicin,
Pelvic Rt, BRT
WD 48 m
Comunog˘lu  et al. [20] 60 No TAH + BSO + PL 125 mm N N Yes 10 N/N No WD 14 m
Gallardo  and Prat [6] 52 No TAH NA Rhabdomyosarcoma NA Yes 6 NA/NA No DWD  35 m
Duggal  et al. [16] 15 No TAH + BSO + Omentectomy 60 mm Chondrosarcoma, myxoid
liposarcoma,
leiomyosarcoma,
rhabdomyosarcoma
N Yes 24 NA/NA 6 cycles
chemotherapy,
Rt
DWD  12 m
Patrelli  et al. [17] 72 No TAH + BSO + PL + Omental
biopsy + Appendectomy
60 mm Rhabdomyosarcoma Yes Yes 10 N/N Pelvic Rt 45 Gy,
ifos-
famide + cisplatin)
WD  3 m
Charﬁ  et al. [18] 26 No TAH 60 mm Rhabdomyosarcoma,
cartilage
NA Yes 25 NA No Lost to
follow-up
Seagle  et al. [19] 54 No RH + BSO + PL + PAL 80 mm N N Yes <1 N/N BRT 25 Gy
iridium-192 + 6
cycles
doxorubicin
WD 66 m
Present  study 39 P/N RH + PNSR 75 mm Cartilage,
rhabdomyoblastic
N Yes 52 P/P Rt, ifos-
famide + cisplatin
AWD  21 m
PAP: Papanicolaou; No: Not performed; N: Negative; P: Positive; HR-HPV: high risk human papilloma virus; NA: Not applicable or not evaluated; TAH: Total abdominal hysterectomy; RH:  Radical hysterectomy; BSO: Bilateral
salpingo-oophorectomy; PL: Pelvic lymphadenectomy; PAL: Para-aortic lymphadenectomy; PNSR: Pelvic nodes suspicious removed; TS: Tumor size (maximal diameter); MI:  Myometrial invasion; SO: Sarcomatous overgrowth;
M  × 10 HPF: Mitoses per 10 high-power ﬁelds (number of mitoses in the stromal component); LVI: Lymphovascular invasion; ADJUV: Adjuvant management; Rt: Pelvic radiotherapy; BRT: Brachytherapy; WD:  Without disease;
AWD:  Alive with disease; DWD: Dead with disease; m:  months.
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Hig. 3. (A) Speculoscopy shows local tumor regrowth in the vaginal vault. (B) Pos
8-ﬂuorodeoxyglucose in the right iliac nodal conglomeration, which measured 4
easuring 76 × 39 mm.  (D) PET-CT shows bony recurrence in the right pubic ramus
. Discussion
Müllerian adenosarcoma of the cervix is relatively rare, account-
ng for approximately 2% of uterine adenosarcomas [1]. It is
xceptionally rare for patients with this disease to present with
arcomatous overgrowth and a heterologous component (present
n 20% of cases), as well as lymph node involvement [2].
The risk factors for diseases of cervical origin are unresolved.
hether radiotherapy is a risk factor for cervical adenosarcoma
s also unclear owing to inconsistent data [3]. No high-risk human
apilloma viruses (HR-HPVs) were detected via hybridization tech-
iques or polymerase chain reaction (PCR) in the 9 cases of
üllerian adenosarcoma examined by Mumba  et al. [4] In our case,
CR was used and HR-HPV DNA was not detected, thus excluding
PV involvement in tumor development.emission tomography-computed tomography (PET-CT) shows intense capture of
 × 57 mm.  (C) PET-CT shows hypermetabolic vaginal vault regrowth and a tumor
In previous cases and case series, total abdominal hysterectomy
was the most frequently performed surgery in patients with tumors
of cervical origin. However, we  recommend radical hysterectomy
aimed at obtaining sufﬁcient tumor-free margins, because most
clinically evident lesions are FIGO stage IB1 or IB2 [5]. As consis-
tently reported, recurrence is more likely when less radical surgical
procedures (e.g., polypectomies that preserve fertility) are per-
formed. This is particularly true among adolescents, and the time
to recurrence varies from 3 to 11 years [6,7]. Bilateral oophorec-
tomy has been widely used to manage Müllerian adenosarcomas
of the uterine corpus. However, for tumors of cervical origin, the
indications for oophorectomy are difﬁcult to establish owing to the
infrequency of these tumors [8].
Myometrial invasion is a signiﬁcant histopathological prog-
nostic factor for adenosarcomas of the uterine corpus. More
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(ig. 4. (A) Posterior speculoscopy at the start of external pelvic radiotherapy shows
lane of the dorsal spine shows vertebral body metastasis with pathological fractu
f  the medullary canal.
ecurrences and lower survival rates have been reported in cer-
ical adenosarcomas with myometrial invasion ranging from the
nternal third to the deep region compared with those with lesser
r no invasion [9].
Lymphovascular or nodal compromise in Müllerian adenosar-
oma of the cervix with sarcomatous overgrowth is poorly
escribed. In a study of 60 patients with 9 cases of adenosarcoma
f the uterine corpus, 4 had local relapse and 3 exhibited stromal
vergrowth; however, there was no lymphovascular compromise
n the 6 cases in which it was assessed [10]. In the case of a tumor
ith sarcomatous overgrowth described by Park et al., pelvic lym-
hadenectomy ruled out retroperitoneal nodal compromise, and
he outcome was good [11].
It is possible that tumors without risk factors for recur-
ence and progression [e.g., sarcomatous overgrowth, high mitotic
ndex, heterologous (rhabdomyoblastic) component, lymphovas-
ular compromise, and myometrial invasion] have better outcomes
ithout adjuvant management, as suggested by others [9,12–14].
owever, we recommend adjuvant chemotherapy consisting of
fosfamide and platinum and pelvic radiotherapy for tumors with
istopathological ﬁndings indicating a high risk of recurrence, as
n the case reported by Manoharan et al. [15] In the study by
anner et al., Müllerian adenosarcomas of the uterus with sarco-
atous growth (n = 5) had much lower progression-free survival
nd global survival rates (both 20%) than did those without sarco-
atous overgrowth (both 100%). Recurrence developed in 4 of the
 (80%) patients with sarcomatous growth, 3 of whom presented
ith myometrial invasion [13]. Table 1 lists the cases of Mülle-
ian adenosarcoma of the cervix with sarcomatous overgrowth and
ther risk factors that have been reported in the English literature
16–20].
Reports of PET-CT as a preoperative procedure for Müllerian
denosarcoma of the cervix or in cases of recurrence are rare. Choi
t al. described a Müllerian adenosarcoma with sarcomatous over-
rowth in the uterine corpus whose disease staging and diagnosis
f progression were achieved via PET-CT [21]. In our study, PET-CT
as used to identify relapse locations in addition to those detected
ia clinical examination of the vaginal vault. However, whether
ET-CT is indicated for the initial detection of lymph node and
one metastases in FIGO stage IB tumors with surgical indication
s unclear.. Conclusion
This case illustrates the need for sequential pelvic radiotherapy
external and brachytherapy) and chemotherapy for the treatmentr reduction in tumor volume. (B) Magnetic resonance imaging (MRI) in the sagittal
he T12 vertebra. (C) MRI  at the T12 level shows inﬁltrative metastatic compromise
of patients with cervical Müllerian adenosarcomas presenting risk
factors for recurrence. Radiotherapy and ifosfamide and platinum
chemotherapy may  aid recurrent disease control.
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